MERCK & CO. INC. (6MK.DE) Stock Price & Overview

FRA:6MK • US58933Y1055

Current stock price

104.6 EUR
+1 (+0.97%)
Last:

The current stock price of 6MK.DE is 104.6 EUR. Today 6MK.DE is up by 0.97%. In the past month the price increased by 0.58%. In the past year, price increased by 26.79%.

6MK.DE Key Statistics

52-Week Range65.5 - 106
Current 6MK.DE stock price positioned within its 52-week range.
1-Month Range97.4 - 105
Current 6MK.DE stock price positioned within its 1-month range.
Market Cap
258.612B
P/E
13.14
Fwd P/E
23.32
EPS (TTM)
7.96
Dividend Yield
2.86%

6MK.DE Stock Performance

Today
+0.97%
1 Week
+5.66%
1 Month
+0.58%
3 Months
+17.40%
Longer-term
6 Months +56.82%
1 Year +26.79%
2 Years -14.26%
3 Years +7.39%
5 Years +58.97%
10 Years N/A

6MK.DE Stock Chart

MERCK & CO. INC. / 6MK Daily stock chart

6MK.DE Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to 6MK.DE. When comparing the yearly performance of all stocks, 6MK.DE is one of the better performing stocks in the market, outperforming 88.6% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

6MK.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to 6MK.DE. 6MK.DE has an excellent profitability rating, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

6MK.DE Earnings

On February 3, 2026 6MK.DE reported an EPS of 2.09 and a revenue of 16.40B. The company beat EPS expectations (2.98% surprise) and beat revenue expectations (0.31% surprise).

Next Earnings DateApr 30, 2026
Last Earnings DateFeb 3, 2026
PeriodQ4 / 2025
EPS Reported$2.09
Revenue Reported16.4B
EPS Surprise 2.98%
Revenue Surprise 0.31%

6MK.DE Forecast & Estimates

36 analysts have analysed 6MK.DE and the average price target is 108.2 EUR. This implies a price increase of 3.44% is expected in the next year compared to the current price of 104.6.

For the next year, analysts expect an EPS growth of -43.62% and a revenue growth 3.06% for 6MK.DE


Analysts
Analysts77.78
Price Target108.2 (3.44%)
EPS Next Y-43.62%
Revenue Next Year3.06%

6MK.DE Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

6MK.DE Financial Highlights

Over the last trailing twelve months 6MK.DE reported a non-GAAP Earnings per Share(EPS) of 7.96. The EPS increased by 20.16% compared to the year before.


Income Statements
Revenue(TTM)65.01B
Net Income(TTM)18.25B
Industry RankSector Rank
PM (TTM) 28.08%
ROA 13.34%
ROE 34.7%
Debt/Equity 0.89
Chartmill High Growth Momentum
EPS Q2Q%21.51%
Sales Q2Q%4.97%
EPS 1Y (TTM)20.16%
Revenue 1Y (TTM)1.31%

6MK.DE Ownership

Ownership
Inst Owners81.17%
Shares2.47B
Float2.47B
Ins Owners0.05%
Short Float %N/A
Short RatioN/A

About 6MK.DE

Company Profile

6MK logo image Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

Company Info

IPO: 1941-01-01

MERCK & CO. INC.

126 East Lincoln Avenue, P.O. Box 2000

Rahway NEW JERSEY US

Employees: 75000

6MK Company Website

6MK Investor Relations

Phone: 19087404000

MERCK & CO. INC. / 6MK.DE FAQ

Can you describe the business of MERCK & CO. INC.?

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.


What is the current price of 6MK stock?

The current stock price of 6MK.DE is 104.6 EUR. The price increased by 0.97% in the last trading session.


Does 6MK stock pay dividends?

MERCK & CO. INC. (6MK.DE) has a dividend yield of 2.86%. The yearly dividend amount is currently 2.84.


What is the ChartMill rating of MERCK & CO. INC. stock?

6MK.DE has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


What sector and industry does MERCK & CO. INC. belong to?

MERCK & CO. INC. (6MK.DE) operates in the Health Care sector and the Pharmaceuticals industry.


Who owns MERCK & CO. INC.?

You can find the ownership structure of MERCK & CO. INC. (6MK.DE) on the Ownership tab.